CN113045550A - 一种三氮唑类衍生物及其制备方法和应用 - Google Patents
一种三氮唑类衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN113045550A CN113045550A CN202110267569.4A CN202110267569A CN113045550A CN 113045550 A CN113045550 A CN 113045550A CN 202110267569 A CN202110267569 A CN 202110267569A CN 113045550 A CN113045550 A CN 113045550A
- Authority
- CN
- China
- Prior art keywords
- disorders
- pharmaceutically acceptable
- crm1
- triazole derivative
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003852 triazoles Chemical class 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 102100029095 Exportin-1 Human genes 0.000 claims abstract description 41
- 108700002148 exportin 1 Proteins 0.000 claims abstract description 41
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 claims abstract description 40
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 claims abstract description 40
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims abstract description 40
- 101150094313 XPO1 gene Proteins 0.000 claims abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 230000000694 effects Effects 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 44
- 208000035475 disorder Diseases 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 235000020932 food allergy Nutrition 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 235000012631 food intake Nutrition 0.000 claims description 2
- 208000037824 growth disorder Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 230000008467 tissue growth Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 5
- 150000007980 azole derivatives Chemical class 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- -1 c-Ab1 Proteins 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- JFBAVWVBLRIWHM-AWNIVKPZSA-N (e)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-2-pyrimidin-5-ylprop-2-enamide Chemical compound C=1N=CN=CC=1/C(C(=O)N)=C\N(N=1)C=NC=1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JFBAVWVBLRIWHM-AWNIVKPZSA-N 0.000 description 16
- 108010057466 NF-kappa B Proteins 0.000 description 16
- 102000003945 NF-kappa B Human genes 0.000 description 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000007832 Na2SO4 Substances 0.000 description 8
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 8
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 230000030147 nuclear export Effects 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- YACHGFWEQXFSBS-XYERBDPFSA-N leptomycin B Chemical compound OC(=O)/C=C(C)/C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)/C=C(\C)/C=C/C[C@@H](C)/C=C(/CC)\C=C\[C@@H]1OC(=O)C=C[C@@H]1C YACHGFWEQXFSBS-XYERBDPFSA-N 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 239000011259 mixed solution Substances 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 206010012310 Dengue fever Diseases 0.000 description 5
- 241000725619 Dengue virus Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 239000000225 tumor suppressor protein Substances 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 101100202237 Danio rerio rxrab gene Proteins 0.000 description 4
- 101100309320 Danio rerio rxrga gene Proteins 0.000 description 4
- 239000001116 FEMA 4028 Substances 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 101150050070 RXRA gene Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229960004853 betadex Drugs 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 108010038912 Retinoid X Receptors Proteins 0.000 description 3
- 102000034527 Retinoid X Receptors Human genes 0.000 description 3
- 208000009714 Severe Dengue Diseases 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VREVSIZDNGOZRO-UHFFFAOYSA-N 5-[3,5-bis(trifluoromethyl)phenyl]-1h-1,2,4-triazole Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NNC=N2)=C1 VREVSIZDNGOZRO-UHFFFAOYSA-N 0.000 description 2
- 108700020463 BRCA1 Proteins 0.000 description 2
- 102000036365 BRCA1 Human genes 0.000 description 2
- 101150072950 BRCA1 gene Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102100024310 COMM domain-containing protein 1 Human genes 0.000 description 2
- 101100450705 Caenorhabditis elegans hif-1 gene Proteins 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 2
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 108010036115 Histone Methyltransferases Proteins 0.000 description 2
- 102000011787 Histone Methyltransferases Human genes 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000909580 Homo sapiens COMM domain-containing protein 1 Proteins 0.000 description 2
- 101000895882 Homo sapiens Transcription factor E2F4 Proteins 0.000 description 2
- 101000775102 Homo sapiens Transcriptional coactivator YAP1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 229930190887 Leptomycin Natural products 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 102100021783 Transcription factor E2F4 Human genes 0.000 description 2
- 102100031873 Transcriptional coactivator YAP1 Human genes 0.000 description 2
- 102100023870 YLP motif-containing protein 1 Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- KDZWTGYCFWOXMR-SDQBBNPISA-N n1n(/C=C(\Br)C(=O)OC(C)C)cnc1-c1cc(C(F)(F)F)cc(C(F)(F)F)c1 Chemical compound n1n(/C=C(\Br)C(=O)OC(C)C)cnc1-c1cc(C(F)(F)F)cc(C(F)(F)F)c1 KDZWTGYCFWOXMR-SDQBBNPISA-N 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000030648 nucleus localization Effects 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- UZHPDUPJPCREDG-AWNIVKPZSA-N (e)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-2-pyrimidin-5-ylprop-2-enoic acid Chemical compound C=1N=CN=CC=1/C(C(=O)O)=C\N(N=1)C=NC=1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UZHPDUPJPCREDG-AWNIVKPZSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- DKNBQCNMOMOSNR-UHFFFAOYSA-N 1-phenyl-n-(trifluoromethyl)methanesulfonamide Chemical compound FC(F)(F)NS(=O)(=O)CC1=CC=CC=C1 DKNBQCNMOMOSNR-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- CZKHHAOIHXHOSR-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC(C#N)=CC(C(F)(F)F)=C1 CZKHHAOIHXHOSR-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000724653 Borna disease virus Species 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- HUEYLTPONFCYRW-WDZFZDKYSA-N CCOC(/C(\Br)=C/N1N=C(C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)N=C1)=O Chemical compound CCOC(/C(\Br)=C/N1N=C(C2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)N=C1)=O HUEYLTPONFCYRW-WDZFZDKYSA-N 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 101100222017 Candida albicans (strain SC5314 / ATCC MYA-2876) CSA2 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 101100234405 Dictyostelium discoideum kif5 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 102100021454 Histone deacetylase 4 Human genes 0.000 description 1
- 102100021453 Histone deacetylase 5 Human genes 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000899259 Homo sapiens Histone deacetylase 4 Proteins 0.000 description 1
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 description 1
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 1
- 108700020121 Human Immunodeficiency Virus-1 rev Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102000016878 Hypoxia-Inducible Factor 1 Human genes 0.000 description 1
- 108010028501 Hypoxia-Inducible Factor 1 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108010062228 Karyopherins Proteins 0.000 description 1
- 102000011781 Karyopherins Human genes 0.000 description 1
- 102100020680 Krueppel-like factor 5 Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 101100510217 Mus musculus Kif5a gene Proteins 0.000 description 1
- BYYIQQAFAMOLSN-UHFFFAOYSA-N NSCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 Chemical compound NSCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BYYIQQAFAMOLSN-UHFFFAOYSA-N 0.000 description 1
- 208000008636 Neoplastic Processes Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 101710184164 ORF3b protein Proteins 0.000 description 1
- 206010068786 Overlap syndrome Diseases 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical class [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
- 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 101710087130 Zinc finger CCCH-type antiviral protein 1 Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 125000005619 boric acid group Chemical group 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- QWVNYBWNXRRADG-WAYWQWQTSA-N ethyl (z)-3-[5-(2-amino-5-chlorophenyl)-1,2,4-triazol-1-yl]prop-2-enoate Chemical compound CCOC(=O)\C=C/N1N=CN=C1C1=CC(Cl)=CC=C1N QWVNYBWNXRRADG-WAYWQWQTSA-N 0.000 description 1
- AELYFQSZXFFNGP-ARJAWSKDSA-N ethyl (z)-3-iodoprop-2-enoate Chemical compound CCOC(=O)\C=C/I AELYFQSZXFFNGP-ARJAWSKDSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Inorganic materials Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- PBDNOFLCGXVKLF-UHFFFAOYSA-N n-methoxyhydroxylamine;hydrochloride Chemical compound Cl.CONO PBDNOFLCGXVKLF-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- IWDFQMHSASFYKY-UHFFFAOYSA-N propan-2-yl 3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-2,3-dibromopropanoate Chemical compound CC(C)OC(=O)C(Br)C(Br)N1C=NC(C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=N1 IWDFQMHSASFYKY-UHFFFAOYSA-N 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- HZFPPBMKGYINDF-UHFFFAOYSA-N pyrimidin-5-ylboronic acid Chemical compound OB(O)C1=CN=CN=C1 HZFPPBMKGYINDF-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
技术领域
本发明属于医药技术领域,具体涉及一种三氮唑类衍生物及其制备方法和应用。
背景技术
目前,恶性肿瘤仍然是威胁人们生命的主要疾病之一。癌症的治疗虽然已经取得了很大的进步,但还未能从根本上治疗癌症。目前上市的抗癌药物虽然具有一定的疗效,但它们大多是细胞毒药物,具有严重的毒副作用。因此,如何从有效的肿瘤靶点出发来研究靶向性的新型抗癌药物成为医药工作者的当务之急。
来自大部分主要人类实体和血液系统恶性肿瘤的细胞表现出多种致癌蛋白、肿瘤抑制蛋白、以及细胞周期调控子的异常细胞定位。例如,某些p53突变可导致细胞基质定位,而非细胞核定位。这导致了正常生长调控的缺失,尽管肿瘤抑制功能是完整的。在其他瘤中,野生型p53被隔离在细胞质中或被迅速降解,再次导致其抑制因子功能的丧失。功能性p53蛋白的恰当的核定位的恢复可使肿瘤性细胞的一些特性正常化,可恢复癌细胞对DNA损伤剂的敏感度,并且可导致长成的肿瘤消退。从其他肿瘤抑制蛋白如叉头和Sullivar和c-Abl中获得了类似数据。此外,一些肿瘤抑制因子和生长调控蛋白的异常定位可能与自身免疫性疾病的发病机理有关。CRM1抑制可在家族性症综合征中提供特別有意义的应用(例如,由一个p53等位基因缺失引起的李一佛美尼综合征、BRCA1或BRCA2癌症综合征),其中特异的肿瘤抑制蛋白(TSP)被清除或具有功能障碍,并且其中通过系统的(或局部的)CRM1抑制剂的给予实现的TSP水平的提高能够帮助恢复正常的肿瘤抑制功能。
特异的蛋白和RNA由特异的转运分子输入和输出细胞核,若它们将分子输入细胞核,则这被分类为输入蛋白,若它们将分子输出细胞核,则被分类为输出蛋白。被输入或输出细胞核的蛋白质包含核输入定位(NLS)或核输出(NES)序列,使它们与相关的转运因子相互作用。染色体区域稳定蛋白1(CRM1),也称作输出蛋白-1或Xpol,为主要的输出蛋白。CRMl的抑制剂阻断抑制蛋白和生长调节因子如p53、c-Ab1、p21、p27、pRB、BRCA1、IkB、ICp27、E2F4、KLF5、YAP1、ZAP、KIF5、HDAC4、HDAC5或叉头蛋白(例如FOXO3a)的核输出,它们与基因表达、细胞增殖、血管生成以及表现遗传相关。有结果表明CRM1抑制因子可诱导癌细胞的凋亡,甚至是在致激活信号或生长激活信号存在的情况下,而不影响正常的(未被转化的)细胞。大多数关于CRM1的功能研究都是使用天然产物来普霉素B(LMB)进行的。来普霉素本身对肿瘤细胞具有很高的毒性,但因较大的胃肠毒性很难用于临床。衍生LMB来改善类药特性可得到保留抗肿活性并且可被动物肿模型更好地耐受的化合物。因此,核输出抑制剂对肿瘤性紊乱及其他增生性素乱可具有有益效果。然而至今,用于在体外和体内使用的小分子的类药CRM1抑制剂仍然有一定的缺陷。
除肿瘤抑制蛋白外,CRM1还输出若干与很多炎性过程相关的关键蛋白。这些蛋白包括IkB、NF-kB、Cox-2、RXRa、Commal、HIFI、HMGBI、FOXO、FOXP等。因为能够引发免疫球蛋白x基因表达的发现而得名的核因子xB(NF-kB/rel)族的转录激活因子可调控各种与炎症、增殖、免疫与细胞存活相关的基因的mRNM表达。在基本情况下,一种称为IkB的NF-kB蛋白抽剂,在核内与NF-kB结合,且IKB-NF-kB复合物使NF-kB的转录功能失活。在炎症刺激的应答中,IkB从IkBNF-kB复合物中解离,释放NF-kB,同时恢复其潜在的转录活性很多激活NF-kB的信号就是通过靶向IkB蛋白水解来做到这些(IkB的磷酸化可“标记”它进行泛素化然后蛋白水解)。核IkBa-MF-kB复合物可被CRM1输出到细胞质,在细胞质中该复合物解离,从而使NF-kB重新激活。泛素化的IkB还可以从NF-kB复合物上解离,恢复NF-kB的转录活性。通过IMB的在人嗜中性细胞和类巨噬细胞(U937)中CRM1诱导的输出的抑制不仅导致无转录活性的核IkBa-NF-kB复合物的累积,还防止了初始的NF-kB激活,甚至是在细胞的刺激下。在一项不同研究中,在肺毛微血管内皮细胞中,用LMB处理抑制了IL-1β诱导的F-KB DNA结合(NF-kB转录激活的第1个步骤)、1L-8表达以及胞间黏附分子表达。COMMD1是NF-kB和缺氧诱导因子1(HIF1)两者的转录活性的另一种核抑制剂。通过抑制CRMl阻断COMMD1的核输出可导致对NF-kB和HIF1的转录活性的抑制的增加。
CRM1还介导类视黄醇X受体a(RXRa)运输。RXRa在肝脏中高度表达并且在调控胆汁酸、胆固醇、脂肪酸、类固醇和异生物质代讲以及内环境稳定中起到核心作用。在肝炎期间,核RXRa水平显著降低,主要归因于通过CRM1的炎症介导的RXRa核输出。在人肝源性细胞中,LepB能够阻止L-1B诱导的细胞质的RXRa水平增加。
在NF-kB、HIF-1和RXRa信号转导中CRM1介导的核输出的作用表明阻断核输出对于很多跨多组织和器官的炎症过程可以有潜在的益处,包括脉管系统(血管炎、动脉炎、风湿性多肌痛、动脉粥样硬化)、皮肤病、风湿病(类风湿及相关关节炎、银屑病关节炎、脊椎关节病、结品性关节病、系统性红斑狼疮、混合性结缔组织病、炎综合征、皮肌炎、包涵体肌炎、未分化结缔组织病、干燥综合征、硬皮病以及重叠综合征等)
抑制CRM1可通过抑制激活一系列转录因子像ICp27、E2F4、KL5、YAP1、ZAP来影响基因表达。
抑制CRM1对很多皮肤科综合征有潜在的治疗破果,包括炎性皮肤病(特应性、变应性皮炎、化学性皮炎、银屑病)、阳光损伤(外线/V损伤)和感染。用LMB研究的最充分的CRM1抑制对正常的角质化细胞呈现最小的作用,且对在UV、TNFa或其他炎症刺激下的角质化细胞呈现抗炎活性。抑制CRM1还可上调NRF2(核因子2相关因子2)的活性,NRF2可保护角质化细胞免于氯化损伤。LMB诱导被致性人乳头瘤病毒(PV)毒株如IPV16感染的角质化细胞的调亡,但不诱导未被感染的角质化细胞的亡。
CRM1还介导关键神经保护蛋白的转运,这些神经保护蛋白可能对神经退行性疾病包括帕金森氏病(PD)、阿尔茨海默病和肌菱缩性侧索硬化症有用。例如,(1)对关键神经保护调控因子如NRF2的强制核阻留,停泊在神经细胞中,和/或通过(2)将1XB隔离于神经胶质细胞的细胞核实现NF-kB的转录活性的抑制,抽制CRM1可减缓或防止这些素乱中发现的神经细胞死亡。还有证据表明,异常的神经胶质细胞增殖与CRM1水平或CRM1功能的异常相关。
很多病毒的完整的成熟也要求主要由CRM1介导的完整的核输出。生命周期里牵涉到核输出和/或CRM1自身的病毒包括人类免疫缺陷病毒(HIV)、腺病毒、猴I型逆转录病毒、波尔纳病(Borna disease)病毒、流感病毒(常规株以及HINL和禽HN1株)、乙型肝炎病毒(BV)和丙型肝炎病毒(HCV)、人乳头縮病毒(HPV)、呼吸道合胞体病毒(RSY、Dungee、严重急性呼吸器官综合征冠状毒、黄热病毒、西尼罗病毒、单纯疹病毒(SV)、巨细胞病毒(CMV)以及默克尔(Merke1)细胞多瘤病毒(MCV)。
穿过核仁并穿梭于细胞核与细胞质之间的HIV-1Rev蛋白促使未剪接的和单剪接的含有Rev应答元件(RRE)RNA的HIV转录物的通过CRM1输出通路的输出。使用CRM1抑制剂如LepB或PKF050-638实现的Rev介导的RA转运的抑制可以阻止HIV-1的转录过程,抑制新的HIV-1病毒粒子的产生,并且从而降低HIV-1的水平。
登革热病毒(DENV)为常见的节肢动物传播的病毒性疾病登革热(DF)及其更严重的和潜在致命的登革出血热(DHF)的病原体。DHF似乎是由对DENV的过旺的炎症应答导致的,NS5是DENV的最大的也是最保守的蛋白。CRM1调控NS5从细胞核到细胞质的转运,其中NS5的大部分功能是被介导的。抑制CRM1介导的NS5的输出可导致产病毒动力学改变,并且减少炎性趋化因子白细胞介素-8(IL-8)的诱导,为治疗DENV以及其他医学上重要的黄病毒包括丙型肝炎病毒引发的疾病提供了一个新的途径。
其他使用CRM1输出细胞核的病毒编码的RNA结合蛋白包括HSVI型间层蛋白(P13/14或HUA7)、人CMV蛋白pp65、SARS冠状病毒ORF3b蛋白、以及RSV基质(M)蛋白。
有趣的是,很多这些病与特定类型的人类癌症相关,这些癌症包括归因于慢性HBV或HCV感染的肝细胞癌(HCC)、归因于HPV的宫颈癌以及与MCV相关的默克尔细胞癌。因此CRM1抑制因子对病毒感染过程及这些病毒引起的肿瘤性转化过程均有益。
CRM1控制核定位,并且从而控制多种DNA代谢酶的活性,这些例包括组蛋白脱乙酰基酶(HDAC)、组蛋白乙酰转移酶(HAT)和组蛋白甲基转移酶(HMT)。
CRM1也与其他紊乱相关。一种以视网膜神经节细胞的退化和视觉失为特征的遗传疾病-莱博病(Lebers disorder)与CRM1开关的无效相关。还有证据表明,神经退行性紊乱和异常的核转运有关。
发明内容
本发明的目的是提供一种三氮唑类衍生物及其制备方法和应用,该三氮唑类衍生物可作为CRM1抑制剂,用于制备与CRM1活性相关疾病的治疗药物。
为了实现上述发明目的,本发明采用以下技术手段:
一种三氮唑类衍生物或其药学上可接受盐,所述三氮唑类衍生物结构如式I所示,
其中:R选自羟基、C1-6烷基、C1-6烷氧基或-C(OR1)(=NR2);
R1和R2独立地为氢、C1-6烷基、卤代C1-6烷基或C1-6烷氧基。
进一步地,所述R选自羟基、C1-4烷基、C1-4烷氧基或-C(OR1)(=NR2);
R1和R2独立地为氢或C1-4烷基。
进一步地,所述三氮唑类衍生物选自以下化合物:
上述三氮唑类衍生物或其药学上可接受盐的制备方法,按如下所示路线进行合成:
一种用于治疗与CRM1活性相关疾病、紊乱或症状的药物组合物,包括上述三氮唑类衍生物或其药学上可接受盐,以及药学上可接受的载体。
上述三氮唑类衍生物或其药学上可接受盐在制备用于治疗与CRM1活性相关的紊乱的药物中的应用。
进一步地,所述与CRM1活性相关的紊乱为增生性紊乱、癌症、炎症性紊乱、自身免疫性紊乱、病毒感染、眼科紊乱、神经退行性紊乱、异常组织生长紊乱、与食物摄取有关的紊乱、过敏以及呼吸紊乱。
进一步地,所述与CRM1活性相关的紊乱为癌症。
进一步地,所述与CRM1活性相关的紊乱为多发性骨髓瘤。
有益效果:细胞活性结果表明,本发明的化合物I和IV与KPT8602基本相当。化合物I的口服和静脉的半衰期均比KPT-8602的口服及静脉的半衰期长,特别是口服的半衰期长约2倍,而且化合物I的静脉和口服的AUC均远高于KPT-8602,表现出更好的药物动力学性质。此外,化合物I表现出良好的安全性。
附图说明
图1为化合物I的BALB/C体内毒性实验结果。
具体实施方式
化合物的定义
本发明的化合物包括在上文中总体上描述的那些,并且通过在此披露的类别、子类别以及种类进一步描述。如在此使用的,除非另外指明,应当使用下面的定义。出于本发明的目的,根据元素周期表,CAS版本,化学和物理手册(Handbook of Chemistry andPhysics),第75版对这些化学元素进行鉴定。
在本说明书之内除非另外说明,在本说明书中使用的命名法总体上遵循在Nomenclature of Organic Chemistry(有机化学命名法),A、B、C、D、E、F、和H章节,对于它的示例性的化学结构命化合物的名称。
本发明的化合物可以具有不对称中心、手性轴以及手性平面,并且作为外消旋体、外消旋混合物以及单个的非对映异构体或者对映异构体存在,其中全部可能的异构体及其混合物(包括旋光异构体)被包括在本发明中。
所谓“卤素”,包含氟原子、氯原子、溴原子及碘原子。特别优选为氟原子及氯原子。
所谓“烷基”,包含碳原子数1~15、优选为碳原子数1~10、更优选为碳原子数1~6、进一步优选为碳原子数1~4的直链或支链状的烃基。例如可列举:甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、异戊基、新戊基、正己基、异己基、正庚基、异庚基、正辛基、异辛基、正壬基、正癸基等。
所谓“烷氧基”,意指上述“烷基”键合于氧原子而成的基团。例如可列举:甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、叔丁氧基、异丁氧基、仲丁氧基、戊氧基、异戊氧基、己氧基等。
作为“烷氧基”的优选实施方式,可列举:甲氧基、乙氧基、正丙氧基、异丙氧基、叔丁氧基。
所谓“卤代烷基”包括:1个以上的上述“卤素”置换上述“烷基”的与碳原子键合的氢原子而成的基团。例如可列举:单氟甲基、单氟乙基、单氟丙基、2,2,3,3,3-五氟丙基、单氯甲基、三氟甲基、三氯甲基、2,2,2-三氟乙基、2,2,2-三氯乙基、1,2-二溴乙基、1,1,1-三氟丙烷-2-基等。
作为“卤代烷基”的一个实施方式,可列举:三氟甲基、三氯甲基。
本发明提供了一种组合物,该组合物包括本发明的化合物或其药学上可接受的行生物以及一种药学上可接受的体、佐剂或运载体。本发明组合物中的化合物的量是这样,使得其在生物样品或者中有效地适度抑制CRW1。在某些实施例中,配制用于向需要此类组合物的患者给药的木发明的一种组合物。如在此使用的,术语“者”意指一种动物。在一些实施例中,该动物是一种乳动物。在某些实施例中,该患者是种兽用患者(即,非人类乳动物患者)。
术语药学可接受的载体、佐剂或运载体”是指不会破坏与其一起配的化物的药理学活性的无毒载体、,佐剂或运载体。可以在本发明的组合物中使用的药学上可接受的载体,佐剂或运载体包括但不限于离子交换剂、氧化铝、硬脂酸铝、卵磷脂、血清蛋白(如人血清白蛋白)、缓冲物质(如酸盐)、甘氨酸、山梨酸、山梨酸钾、饱和植物脂防酸的偏甘油混合物、水、盐或电解质(如硫酸精蛋白、磷酸氢二钠、磷酸氢钾、氯化钠、锌盐)、胶体二氧化硅、三硅酸镁,聚乙烯吡咯烷酮、基于纤维素的物质、聚乙二醇、羧甲基纤素钠、聚丙烯酸酸、蜡、聚乙烯一聚氧丙烯嵌段聚合物、乙二醇以及羊毛脂。
所述三氮唑衍生物或其药物可接受盐的制备方法,按如下所示路线进行合成:
该反应式中各基团R定义如前所述;式(1)在硫氢化钠作用下反应得到式(2),式(2)发生亲核取代生成(3)。式(3)再和溴水、三乙胺作用下反应生成式(4),式(4)发生偶联反应生成(5),式(5)在LiOH的作用下水解成羧酸式(6),式(6)和胺类底物缩合得到式I化合物。
以下详述本发明化合物的制备方法:
化合物1的氰基在硫氢化钠和氯化镁的作用下生成硫代甲酰胺,再在水合肼和甲酸的条件下反应生成三氮唑2,2再在三乙烯二胺的催化作用下与(Z)-3-碘代丙烯酸异丙酯偶联生成化合物3,然后,化合物3的双键部分与液溴发生加成,再在三乙胺的作用下脱去一分子溴得到关键中间体4,中间体4在二(三苯基膦)二氯化钯的催化作用下,分别与带有硼酸结构的多种含氮芳香基发生Suzuki偶联,生成了连接有不同含氮芳香基的化合物5,最后化合物5的酯键在LiOH的作用下水解成羧酸化合物6,羧酸化合物6进一步进行缩合得到目标式I化合物。
下面结合附图和具体实施例对本发明作进一步详细说明,但不应理解为对本发明的限制。在不背离本发明精神和实质的情况下,对本发明方法、步骤或条件所作的修改或替换,均属于本发明的范围。实施例中未注明具体条件的实验方法及未说明配方的试剂均为按照本领域常规条件。
实施例1
一、化合物的合成
本发明的化合物的制备可按照如下过程实施:
化合物I的路线设计与合成
(Z)-3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)丙烯酸异丙酯(3)的合成
在250mL茄形瓶中,加入3,5-双(三氟甲基)苯腈1(10g,41.8mmol),溶于DMF(50mL)溶液中,依次加入NaSH(7.8g,83.7mmol)和MgCl2(8.5g,41.8mmol)。然后将反应在室温下继续搅拌3h。TLC监测反应完全后将反应液倒入冰水混合溶液(500mL)中。用乙酸乙酯(100mL×3)萃取,合并有机相并用饱和氯化钠溶液(100mL×1)洗涤,无水Na2SO4干燥,过滤并减压蒸除溶剂得粗品3,5-双(三氟甲基)苯甲硫酰胺(10.9g,收率95.1%,纯度84%),为黄色油状液体,MS(ESI)m/z 274.35[M+H]+。直接用于下一步使用。
在250mL茄形瓶中,加入3,5-双(三氟甲基)苯甲硫酰胺(10.9g,39.8mmol),溶于DMF(30mL)溶液中,在室温下向其中滴加80%水合肼(5.1mL,83.6mmol)。将混合物继续搅拌1h,然后向其中滴加甲酸(30mL)。然后将反应在90℃下继续搅拌3h。TLC监测反应完全后,将反应降至室温,将反应液倾倒入纯净水(600mL)中。用乙酸乙酯(100mL×3)萃取,合并有机相并用饱和碳酸氢钠溶液(300mL×3)和饱和氯化钠溶液(100mL×1)洗涤,无水Na2SO4干燥,过滤并减压蒸除溶剂得化合物粗品。用正己烷(200mL×3)搅洗,过滤并干燥后得到3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑2(8.5g,收率76.0%,纯度90%),白色固体。1HNMR(400MHz,CDCl3)δ8.63(s,2H,Ph),8.40(s,1H,NCH),8.02(d,J=13.8Hz,1H,NCHCH),7.95(s,1H,Ph),6.74(d,J=13.8Hz,1H,NCHCH)MS(ESI)m/z 279.89[M+H]+。
在250mL茄形瓶中,加入3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑2(8.5g,30.2mmol),溶于DMF(40mL)中,向其中加入DABCO(8.5g,75.5mmol)。将混合物在室温下继续搅拌30min后,向反应液中滴加(Z)-3-碘代丙烯酸乙酯(7.5g,33.2mmol)。然后将反应在室温下继续搅拌3h。TLC监测反应完全后,将反应液倒入冰水混合溶液(400mL)中。用乙酸乙酯(80mL×3)萃取,合并有机相并用饱和氯化钠溶液(100mL×1)洗涤,无水Na2SO4干燥,过滤并减压蒸除溶剂得化合物粗品。将得到的粗品通过柱色谱(PE/EtOAc=25:1)纯化,得到化合物(Z)-3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)丙烯酸乙酯3(7.9g,收率68.2%,纯度98%),为白色固体。1H NMR(400MHz,CDCl3)δ8.63(s,2H,Ph),8.40(s,1H,NCH),8.02(d,J=13.8Hz,1H,NCHCH),7.95(s,1H,Ph),6.74(d,J=13.8Hz,1H,NCHCH),4.87(m,1H,CH),1.36(t,J=7.1Hz,6H,Me).MS(ESI)m/z 394.23[M+H]+。
(Z)-3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-2-溴丙烯酸异丙酯(4)的合成
在250mL的茄形瓶中,将之前得到的(Z)-3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)丙烯酸乙酯3(7.9g,20.6mmol)溶于二氯甲烷(40mL)中。在30min内,向其中缓慢滴加液溴(6.6g,41.2mmol),然后将反应于室温下继续搅拌8h。TLC监测反应完全后,将反应液倒入冰水混合溶液(100mL)中。用二氯甲烷(50mL×3)萃取,合并有机相并用饱和亚硫酸氢钠溶液(100mL×3)和饱和氯化钠溶液(50mL×1)洗涤,无水Na2SO4干燥,过滤并减压蒸除溶剂。柱色谱(PE/EtOAc=50:1)分离纯化,得到3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-2,3-二溴丙酸异丙酯(10.3g,收率92.7%,纯度95%),为白色固体。MS(ESI)m/z 551.97[M+H]+。
将上一步得到的中间体3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-2,3-二溴丙酸异丙酯(10.3g,19.1mmol)称取至250mL茄形瓶中,用四氢呋喃(40mL)溶解后,在冰浴下搅拌10min后,向反应液中滴加三乙胺(3.9g,38.2mmol)并继续搅拌30min。然后将反应移至室温下继续搅拌6h。TLC监测反应完全后,向反应液中加入冰水混合溶液(100mL)。用乙酸乙酯(50mL×3)萃取,合并有机相并用饱和氯化钠溶液(50mL×1)洗涤,无水Na2SO4干燥,过滤并减压蒸除溶剂。柱色谱(PE/EtOAc=50:1)分离纯化得到(Z)-3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-2-溴丙烯酸乙酯4(7.7g,收率88.2%,纯度96%),为白色固体。1H NMR(400MHz,CDCl3)δ8.75(s,1H,NCH),8.56(s,2H,Ph),7.93(s,1H,Ph),7.65(s,1H,CBrCH),4.38(m,1H,CH),1.37(t,J=7.1Hz,6H,Me).MS(ESI)m/z 473.09[M+H]+。
(E)-3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-2-(嘧啶-5-基)丙烯酸异丙酯(5)的合成
取一个25ml三颈瓶,分别称取重要中间体4(200mg,0.44mmol)和5-嘧啶硼酸(81.9mg,0.66mmol)溶于二氧六环(5mL)和水(1mL)的混合溶液中。随后称取醋酸钠(86.4mg,0.88mmol)加入反应液,将反应置换氮气3次后在室温下搅拌。然后向反应液中加入Pd(PPh3)Cl2(30.9mg,0.04mmol),并再次用氮气置换反应3次后在80℃下搅拌过夜。TLC监测反应完全后,将反应降至室温,向反应液中加入纯净水(50mL)。用乙酸乙酯(15mL×3)萃取,合并有机相并用饱和氯化钠溶液(20mL×1)洗涤,无水Na2SO4干燥,过滤并真空蒸除溶剂得化合物粗品。通过柱色谱(PE/EtOAc=8:1)分离纯化,得到(E)-3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-2-(嘧啶-5-基)丙烯酸乙酯5(125.3mg,收率62.3%,纯度93%),为白色固体。1H NMR(400MHz,CDCl3)δ9.28(s,1H,Pyrimidine),8.89(s,2H,Pyrimidine),8.72(s,1H,NCH),8.59(s,2H,
Ph),7.96(s,1H,Ph),7.40(s,1H,COCCH),4.85(m,1H,CH),1.36(t,J=7.2Hz,6H,Me).MS(ESI)m/z 472.17[M+H]+。
(E)-3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-2-(嘧啶-5-基)丙烯羧酸(6)的合成
在25mL的茄形瓶中,将5(125.3mg,0.27mmol)溶于四氢呋喃(3mL)中。在冰浴下搅拌10min后,向反应液中滴加LiOH·H2O(45.3mg,1.08mmol)的水(1mL)溶液。继续搅拌30min后将反应移至室温下搅拌过夜。TLC监测反应完全后,将冰水混合溶液(10mL)倒入反应液中,用4N盐酸调节溶液的pH至2-3。用乙酸乙酯(5mL×3)萃取,合并有机相并用饱和氯化钠溶液(20mL×1)洗涤,无水Na2SO4干燥,过滤并减压蒸除溶剂。得到较纯的化合物(E)-3-(3-(3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-2-(嘧啶-5-基)丙烯酸(99.4mg,收率85.8%,纯度89%),为白色固体。直接用于下一步使用。MS(ESI)m/z 427.92[M-H]-。
(E)-3-(3-(3-,3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-N-甲氧基-2-(嘧啶-5-基)丙烯酰胺(I)的合成
25mL的茄形瓶中,将6(125.3mg,0.27mmol)溶于二氯乙烷(3mL)中。在冰浴下搅拌10min后,向反应液中加入EDCI(20.3mg,1.08mmol)和HOBT(70.5mg,1.5mmol)。继续搅拌30min后将反应移至室温下滴加DIPEA(54.5mg,3.0mmol)和甲氧基羟胺盐酸盐(23.4mg,1.0mmol)搅拌过夜。TLC监测反应完全后,将冰水混合溶液(10mL)倒入反应液中。用乙酸乙酯(5mL×3)萃取,合并有机相并用饱和氯化钠溶液(20mL×1)洗涤,无水Na2SO4干燥,过滤并减压蒸除溶剂。得到化合物(E)-3-(3-(3-,3,5-双(三氟甲基)苯基)-1H-1,2,4-三唑-1-基)-N-甲氧基-2-(嘧啶-5-基)丙烯酰胺(35.4mg,收率40%,纯度89%),为白色固体。1HNMR(400MHz,CDCl3)δ8.78(d,J=5.9Hz,2H,Pyridine),8.40(s,2H,Ph),8.33(s,1H,NCH),7.92(s,1H,Ph),7.87(s,1H,COCCH),7.28(d,J=1.6Hz,2H,Pyridine),4.34(t,J=7.1Hz,3H,Me).MS(ESI)m/z 459.10[M+H]+。
合成的具体化合物及其名称如下表。
二、细胞株抑制活性
1.细胞冻存
(1)收获细胞后常温1000转离心5min,PBS漂洗。
(2)含7%DMSO和10%胎牛血清的1640培养基重悬。
(3)分装入冻存管,放入细胞冻存盒中-80℃过夜处理后,液氮保存。
2.细胞复苏与培养:
(1)将冻存管从液氮罐中取出,放入37℃温水中轻轻摇晃,使细胞液解冻。
(2)转入无菌离心管,加入含10%胎牛血清1640培养液,轻轻吹打成悬液。
(3)室温1000转离心5min,弃上清液,加入10%含胎牛血清的1640培养液,轻轻吹打成悬液。
(4)转入培养瓶,于37℃含5%CO2饱和湿度孵箱培养1-2日换液。
3.细胞传代:
弃掉原培基加入无菌PBS冲洗一遍,加入1mL 0.25%的胰酶孵育1分钟左右,镜下观察,待多数细胞开始变圆后小心吸净胰酶,并加入新鲜的培养基终止消化,将细胞吹打成均匀的细胞悬液,转入细胞孵箱中继续培养。
4.细胞毒性实验
(1)将对数生长期的RPMI8226细胞于1000个/well加入384孔板中,体积为18μL/well,在37℃,5%CO2下孵育24h。
(2)将储存浓度为10mM的待测化合物用DMSO稀释10倍后,再用不含血清的1640培养基稀释100倍,得到10μM含1%DMSO的工作浓度,然后2倍梯度稀释,用1%DMSO的无血清1640培养基稀10个浓度,第十个浓度点是溶剂对照组(无药物)。将稀释好的化合物每孔吸取2μL加到铺好的细胞板中,得到化合物终浓度为1000nM起,2倍梯度稀释,10个浓度梯度,每个浓度设4个重复。1%DMSO用作溶剂对照,KPT-8602作为阳性对照。
(3)37℃下孵育72h后,每孔加入10μL的Cell-Titer检测试剂,再置于细胞培养箱孵育10min。
(4)震荡混匀后,于酶标仪运行Cell-Titer程序检测,并用GraphPad Prism 5计算inhibition%和IC50值(μM)。
化合物的细胞结果如下表:
编号 | RPMI8226 | 编号 | RPMI8226 |
KPT-8602 | 0.34 | I | 0.37 |
II | 6.9 | III | 7.1 |
IV | 0.54 |
细胞活性结果表明,化合物I和IV与KPT8602基本相当。
三、药物在SD大鼠的药代动力学结果
结论:化合物I的口服和静脉的半衰期均比KPT-8602的口服及静脉的半衰期长,特别是口服的半衰期长约2倍,而且化合物I的静脉和口服的AUC均远高于KPT-8602,表现出更好的药物动力学性质。
四、候选化合物BALB/C体内毒性实验
将25只BALB/C小鼠随机分为5组:溶剂对照组(Control)、阳性对照KPT-8602(30mg/kg,一天1次)组、KPT-8602(60mg/kg,一天1次)组、化合物I(30mg/kg,一天1次)组、化合物I(60mg/kg,一天1次)组,各组均为5只,各组按3mL/kg的给药容量灌胃给予相应浓度的受试物,KPT-8602和化合物I每天连续给药,共给药21天。
化合物溶液配制方法:
10%磺丁基-β-环糊精配制:
称取5.0g的磺丁基-β-环糊精粉末置于烧杯中,用移液器吸取50mL的柠檬酸缓冲液至烧杯,溶解后转移至容器中。
化合物I的配制:
称取24mg的化合物I,加入1.6mL的20%聚乙二醇水溶液,溶清后再加入10%磺丁基-β-环糊精水溶液6.4mL,得到3mg/mL的化合物I受试物溶液。
KPT-8602的配制:
称取24mg的化合物KPT-8602,加入1.6mL的20%聚乙二醇水溶液,溶清后再加入10%磺丁基-β-环糊精水溶液6.4mL,得到3mg/mL的KPT-8602受试物溶液。
连续给药后小鼠体重变化结果如图1所示。
结论:
如图1所示,KPT-8602的60mg/kg组在第七天有两只小鼠出现死亡,第10天全部死亡。KPT-8602的30mg/kg组体重出现显著的下降。而化合物I的30mg/kg和化合物I的60mg/kg组在21天后体重仍与空白相当,表现出良好的安全性。
Claims (9)
2.根据权利要求1所述的三氮唑类衍生物或其药学上可接受盐,其特征在于:所述R选自羟基、C1-4烷基、C1-4烷氧基或-C(OR1)(=NR2);
R1和R2独立地为氢或C1-4烷基。
5.一种用于治疗与CRM1活性相关疾病、紊乱或症状的药物组合物,其特征在于:包括权利要求1-3任一项所述三氮唑类衍生物或其药学上可接受盐,以及药学上可接受的载体。
6.权利要求1-3任一项所述三氮唑类衍生物或其药学上可接受盐在制备用于治疗与CRM1活性相关的紊乱的药物中的应用。
7.根据权利要求6所述的应用,其特征在于:所述与CRM1活性相关的紊乱为增生性紊乱、癌症、炎症性紊乱、自身免疫性紊乱、病毒感染、眼科紊乱、神经退行性紊乱、异常组织生长紊乱、与食物摄取有关的紊乱、过敏以及呼吸紊乱。
8.根据权利要求7所述的应用,其特征在于:所述与CRM1活性相关的紊乱为癌症。
9.根据权利要求8所述的应用,其特征在于:所述与CRM1活性相关的紊乱为多发性骨髓瘤。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110267569.4A CN113045550A (zh) | 2021-03-12 | 2021-03-12 | 一种三氮唑类衍生物及其制备方法和应用 |
CN202280015399.3A CN116897153A (zh) | 2021-03-12 | 2022-03-11 | 一种三氮唑类衍生物及其制备方法和应用 |
EP22766368.9A EP4306517A1 (en) | 2021-03-12 | 2022-03-11 | Triazole derivative, preparation method therefor, and application thereof |
CA3210944A CA3210944A1 (en) | 2021-03-12 | 2022-03-11 | Triazole derivative, method for preparing same, and use thereof |
AU2022231918A AU2022231918B2 (en) | 2021-03-12 | 2022-03-11 | Triazole derivative, preparation method therefor, and application thereof |
US18/277,099 US20240140934A1 (en) | 2021-03-12 | 2022-03-11 | Triazole derivative, method for preparing same, and use thereof |
KR1020237028581A KR20230134571A (ko) | 2021-03-12 | 2022-03-11 | 트리아졸 유도체 및 이의 제조방법과 응용 |
PCT/CN2022/080255 WO2022188846A1 (zh) | 2021-03-12 | 2022-03-11 | 一种三氮唑类衍生物及其制备方法和应用 |
JP2023552234A JP2024507596A (ja) | 2021-03-12 | 2022-03-11 | トリアゾール系誘導体及びその製造方法並びに使用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110267569.4A CN113045550A (zh) | 2021-03-12 | 2021-03-12 | 一种三氮唑类衍生物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113045550A true CN113045550A (zh) | 2021-06-29 |
Family
ID=76511801
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110267569.4A Pending CN113045550A (zh) | 2021-03-12 | 2021-03-12 | 一种三氮唑类衍生物及其制备方法和应用 |
CN202280015399.3A Pending CN116897153A (zh) | 2021-03-12 | 2022-03-11 | 一种三氮唑类衍生物及其制备方法和应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280015399.3A Pending CN116897153A (zh) | 2021-03-12 | 2022-03-11 | 一种三氮唑类衍生物及其制备方法和应用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20240140934A1 (zh) |
EP (1) | EP4306517A1 (zh) |
JP (1) | JP2024507596A (zh) |
KR (1) | KR20230134571A (zh) |
CN (2) | CN113045550A (zh) |
AU (1) | AU2022231918B2 (zh) |
CA (1) | CA3210944A1 (zh) |
WO (1) | WO2022188846A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022188846A1 (zh) * | 2021-03-12 | 2022-09-15 | 深圳济康医药科技有限公司 | 一种三氮唑类衍生物及其制备方法和应用 |
WO2023072248A1 (zh) * | 2021-10-29 | 2023-05-04 | 正大天晴药业集团股份有限公司 | 含吡啶基的化合物 |
WO2023134629A1 (zh) * | 2022-01-12 | 2023-07-20 | 上海海雁医药科技有限公司 | 核转运调节剂及其用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3010892B8 (en) * | 2013-06-21 | 2019-05-22 | Karyopharm Therapeutics Inc. | 1,2,4-triazoles as nuclear transport modulators and uses thereof |
CN113045550A (zh) * | 2021-03-12 | 2021-06-29 | 深圳济康医药科技有限公司 | 一种三氮唑类衍生物及其制备方法和应用 |
-
2021
- 2021-03-12 CN CN202110267569.4A patent/CN113045550A/zh active Pending
-
2022
- 2022-03-11 WO PCT/CN2022/080255 patent/WO2022188846A1/zh active Application Filing
- 2022-03-11 AU AU2022231918A patent/AU2022231918B2/en active Active
- 2022-03-11 KR KR1020237028581A patent/KR20230134571A/ko unknown
- 2022-03-11 CN CN202280015399.3A patent/CN116897153A/zh active Pending
- 2022-03-11 JP JP2023552234A patent/JP2024507596A/ja active Pending
- 2022-03-11 CA CA3210944A patent/CA3210944A1/en active Pending
- 2022-03-11 US US18/277,099 patent/US20240140934A1/en active Pending
- 2022-03-11 EP EP22766368.9A patent/EP4306517A1/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022188846A1 (zh) * | 2021-03-12 | 2022-09-15 | 深圳济康医药科技有限公司 | 一种三氮唑类衍生物及其制备方法和应用 |
WO2023072248A1 (zh) * | 2021-10-29 | 2023-05-04 | 正大天晴药业集团股份有限公司 | 含吡啶基的化合物 |
WO2023134629A1 (zh) * | 2022-01-12 | 2023-07-20 | 上海海雁医药科技有限公司 | 核转运调节剂及其用途 |
Also Published As
Publication number | Publication date |
---|---|
KR20230134571A (ko) | 2023-09-21 |
WO2022188846A1 (zh) | 2022-09-15 |
US20240140934A1 (en) | 2024-05-02 |
JP2024507596A (ja) | 2024-02-20 |
EP4306517A1 (en) | 2024-01-17 |
AU2022231918A1 (en) | 2023-08-24 |
CN116897153A (zh) | 2023-10-17 |
CA3210944A1 (en) | 2022-09-15 |
AU2022231918B2 (en) | 2024-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113045550A (zh) | 一种三氮唑类衍生物及其制备方法和应用 | |
KR102322794B1 (ko) | 핵수송 조절인자 및 이의 용도 | |
JP7083750B2 (ja) | Irak阻害剤としてのヘテロアリール化合物及びその使用 | |
KR100837420B1 (ko) | 5-히드록시-인돌-3-카르복시산에스테르 유도체 및 이의용도 | |
CN111511729A (zh) | Tlr7/8拮抗剂及其用途 | |
JPH11302173A (ja) | ヒストン脱アセチル化酵素阻害剤 | |
EP3828173A1 (en) | Substituted pyrazoles as human plasma kallikrein inhibitors | |
WO2011012746A2 (es) | Compuestos inhibidores de apaf-1 | |
JPH11509519A (ja) | 非ステロイド系抗炎症剤誘導毒性を予防する組成物および方法 | |
EP3174877B1 (en) | Indolizine derivatives which are applicable to neurodegenerative diseases | |
AU2015269598B2 (en) | Novel quinoline derivatives and their use in neurodegenerative diseases | |
CN101687798A (zh) | 制备用于调节激酶级联的组合物的过程及其使用方法 | |
JP2000510833A (ja) | 抗―ウイルス性化合物群 | |
CN112538069A (zh) | 一种氮唑类衍生物或其药物可接受盐及其制备方法和用途 | |
Tatar et al. | Synthesis, characterization and screening of antimicrobial, antituberculosis, antiviral and anticancer activity of novel 1, 3-thiazolidine-4-ones derived from 1-[2-(benzoylamino)-4-(methylthio) butyryl]-4-alkyl/arylalkyl thiosemicarbazides | |
CN108794517B (zh) | 一种精氨酸酶抑制剂及其制备方法与用途 | |
CN100560568C (zh) | 环酰亚胺类肽金属蛋白酶抑制剂及其应用 | |
EP2917204A1 (fr) | Derives de 1 h-indole-3-carboxamide et leurs utilisation comme antagonistes du p2y12 | |
ES2439322T3 (es) | Derivados de amino alcohol y sus actividades terapéuticas | |
CN106496132B (zh) | N-(4-取代苯基)-2-取代乙酰胺类化合物及其作为sirt2蛋白抑制剂的用途 | |
CN112010774A (zh) | FXIa凝血因子抑制剂、其药物组合物和用途 | |
US11737995B2 (en) | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | |
CN115322120A (zh) | 一类小分子化合物及在制备治疗dhodh介导疾病药物中的用途 | |
JPS634556B2 (zh) | ||
JPH09512836A (ja) | 細胞付着抑制剤としての(−)−(3r)−3−メチル−4−{4−[4−(4−ピリジル)ピペラジン−1−イル]フェノキシ}酪酸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |